Current Appointments & Affiliations
Instructor in the Department of Medicine
·
2020 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Journal Article Oncologist · June 4, 2025 BACKGROUND: Anexelokto (AXL) protein and its ligand, growth arrest specific-6 (GAS6), are important drivers of metastasis in patients with advanced clear cell renal cell carcinoma (ccRCC). Batiraxcept competitively binds GAS6 limiting interaction with AXL ... Full text Link to item CitePembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Journal Article Prostate Cancer Prostatic Dis · June 2025 BACKGROUND: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented. METHODS: Eligible patients had not ... Full text Link to item CiteAssociation of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
Journal Article Eur Urol Oncol · April 2025 BACKGROUND AND OBJECTIVE: Despite curative-intent radical cystectomy (RC), patients with muscle-invasive bladder cancer (MIBC) are at high risk of recurrence. Biomarkers are urgently needed to refine prognostication and selection of appropriate perioperati ... Full text Link to item CiteRecent Grants
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcino
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2029Xencor: ENPP3 BiTe study for ccRCC
Clinical TrialPrincipal Investigator · Awarded by Xencor, Inc · 2023 - 2028View All Grants
Education, Training & Certifications
New York Institute of Technology, College of Osteopathic Medicine ·
2001
D.O.